News
| Feb 10 | Ignore: Nasdaq Short Interest Tables |
| Feb 10 | Zacks #1 Rank Additions for Thursday |
| Feb 09 | Largest Nasdaq Short Interest Percent Decreases as of Jan. 31 |
| Feb 09 | Largest Nasdaq Short Interest Percent Increases as of Jan. 31 |
| Feb 09 | Largest Nasdaq Short Interest Changes as of Jan. 31 |
| Feb 09 | Zacks #1 Rank Additions for Thursday - Tale of the Tape Zacks |
| Feb 06 | ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on... |
| Feb 06 | $acad ............. by judes0096 |
| Feb 03 | 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows |
| Feb 03 | Presenting @ BioCEO&Investor Conference (Feb 13/14): $ACAD $ACHN $ACOR $ADXS $ANX $AEGR $AEZS $AFFY $AGEN $ALKS $ALNY $ANP $ARDM $ARNA $ARIA by abubnic |
| Feb 01 | January effect has been working in 2012! top 5 profitable biotechs: $ILMN, $SNTS, $ACAD, $GENE, $SIGA #BIOTECHS by dmk112 |
| Feb 01 | $ACAD http://stks.co/2CFm long setup by stt2318 |
| Jan 28 | $ACAD http://stks.co/28Vp Long over $1.63. by VexTrades |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company'Âs pipeline emanate from discoveries made using its proprietary drug discovery platform.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ACADIA Pharmaceuticals is up N/A over the last year vs S&P 500 Total Return up N/A, Achillion Pharmaceuticals up N/A, and Acorda Therapeutics up N/A.
- ACAD Total Returns
- ^SPXTR Total Returns
- ACHN Total Returns
- ACOR Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ACAD related companies
Pro Strategies Featuring ACAD
Did ACADIA Pharmaceuticals make it into our Pro Portfolio Strategies?
ACAD Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other ACAD Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Quote.com
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACAD | 1.80 | -0.01 | -0.55% | 95.04M |
| YTEC | 2.48 | 0.00 | 0.00% | 46.97M |
| CCME | 0.08 | 0.04 | 100.00% | |
| GNVC | 2.65 | 0.01 | 0.38% | 34.24M |
| ANX | 0.71 | -0.01 | -0.78% | 18.93M |
| ASEI | 77.02 | 8.74 | 12.80% | 687.02M |
| RKT | 68.04 | 0.53 | 0.79% | 4.80B |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
| WAVX | 2.17 | -0.03 | -1.36% | 180.48M |
| FRP | 4.42 | -0.43 | -8.87% |
